News
The terms of Cycle Pharma's proposal are "economically identical" to the previously evaluated and rejected offer, Vanda said in a statement. Cycle Pharma's $8 per share proposal is an 80% premium ...
England-based rare disease drug maker Cycle Pharma revealed an $8-per-share offer for Vanda, representing a total buyout offer of $466 million.
Cycle Pharmaceuticals reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals for an all-cash consideration of $8.00 per Vanda share. Cycle said it is ...
Vanda Pharmaceuticals Inc. VNDA shares are trading lower after Future Pak withdrew its proposal to purchase the company. “Consistent with the position indicated in its June 13, 2024 letter to ...
Vanda's share price has enjoyed a multi-month rally since a low of $3.47 in early February, rising to $6.50 last week. With the news that Vanda rejected the proposals, shares traded down by about ...
Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ: VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company.
Vanda Pharma surges on $8 a share takeover offer from Cycle Pharma (update) Jun. 06, 2024 9:38 AM ET Vanda Pharmaceuticals Inc. (VNDA) Stock By: Joshua Fineman, SA News Editor 7 Comments ...
The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage biotech's stock took an almost 6% hit on Thursday, following some ...
Explore Vanda Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VNDA.
Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected] Follow us on X @vandapharma ...
Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the stomach. Vanda began studying tradipitant almost 10 ...
What happened Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) fell more than 19% today after the company announced it was pursuing legal action against the U.S. Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results